Patent ID: 11866518
Assignee: BICYCLETX LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 1:
2. The peptide ligand as defined in claim 1, wherein said peptide ligand comprises an amino acid sequence selected from:
Ac-(SEQ ID NO: 1) (hereinafter referred to as Example 1);
Ac-(SEQ ID NO: 2) (hereinafter referred to as Example 2);
Ac-(SEQ ID NO: 3) (hereinafter referred to as Example 3);
tertBuCO-(SEQ ID NO: 3) (hereinafter referred to as Example 6);
R1-(SEQ ID NO: 3) (hereinafter referred to as Example 7);
Ac-(SEQ ID NO: 4) (hereinafter referred to as Example 4);
Ac-(SEQ ID NO: 5) (hereinafter referred to as Example 5);
Ac-(SEQ ID NO: 6) (hereinafter referred to as Example 8);
Ac-(SEQ ID NO: 7) (hereinafter referred to as Example 9);
Ac-(SEQ ID NO: 8) (hereinafter referred to as Example 10);
Ac-(SEQ ID NO: 9) (hereinafter referred to as Example 11);
Ac-(SEQ ID NO: 10) (hereinafter referred to as Example 12);
Ac-(SEQ ID NO: 11) (hereinafter referred to as Example 13);
Ac-(SEQ ID NO: 12) (hereinafter referred to as Example 14);
Octanoyl-(SEQ ID NO: 13) (hereinafter referred to as Example 15);
Ac-(SEQ ID NO: 14) (hereinafter referred to as Example 16);
Ac-(SEQ ID NO: 15) (hereinafter referred to as Example 17);
Ac-(SEQ ID NO: 15)-[dA] (hereinafter referred to as Example 33);
(SEQ ID NO: 15)-COOH (hereinafter referred to as Example 48);
Ac-(SEQ ID NO: 16) (hereinafter referred to as Example 18);
Ac-(SEQ ID NO: 17) (hereinafter referred to as Example 19);
Ac-(SEQ ID NO: 18) (hereinafter referred to as Example 20);
Ac-(SEQ ID NO: 19) (hereinafter referred to as Example 21);
Ac-(SEQ ID NO: 20) (hereinafter referred to as Example 22);
Ac-(SEQ ID NO: 21) (hereinafter referred to as Example 23);
Ac-(SEQ ID NO: 22) (hereinafter referred to as Example 24);
(SEQ ID NO: 23) (hereinafter referred to as Example 252);
Ac-(SEQ ID NO: 23) (hereinafter referred to as Example 25);
Ac-(SEQ ID NO: 23)-[dA] (hereinafter referred to as Example 29);
Ac-(SEQ ID NO: 24) (hereinafter referred to as Example 26);
Ac-(SEQ ID NO: 25) (hereinafter referred to as Example 27);
Ac-(SEQ ID NO: 26) (hereinafter referred to as Example 28);
Ac-(SEQ ID NO: 27) (hereinafter referred to as Example 30);
Ac-(SEQ ID NO: 28) (hereinafter referred to as Example 31);
Ac-(SEQ ID NO: 29) (hereinafter referred to as Example 32);
Ac-(SEQ ID NO: 30) (hereinafter referred to as Example 34);
Ac-(SEQ ID NO: 31) (hereinafter referred to as Example 35);
Ac-(SEQ ID NO: 32) (hereinafter referred to as Example 36);
Ac-(SEQ ID NO: 33) (hereinafter referred to as Example 37);
Ac-(SEQ ID NO: 34) (hereinafter referred to as Example 38);
Ac-(SEQ ID NO: 34)-[dA] (hereinafter referred to as Example 49);
Ac-(SEQ ID NO: 34)-COOH (hereinafter referred to as Example 69);
Ac-(SEQ ID NO: 35) (hereinafter referred to as Example 43);
Ac-(SEQ ID NO: 35)-COOH (hereinafter referred to as Example 39);
Ac-(SEQ ID NO: 36) (hereinafter referred to as Example 40);
Ac-(SEQ ID NO: 37) (hereinafter referred to as Example 41);
A-(SEQ ID NO: 38)-ADGDML (hereinafter referred to as Example 42);
GTDSAE-(SEQ ID NO: 38)-A (hereinafter referred to as Example 45);
Ac-A-(SEQ ID NO: 38)-PLD (hereinafter referred to as Example 53);
Ac-(SEQ ID NO: 38)-APDERD (hereinafter referred to as Example 54);
A-(SEQ ID NO: 38)-DDAHAP (hereinafter referred to as Example 55);
TMEYRD-(SEQ ID NO: 38)-A (hereinafter referred to as Example 56);
A-(SEQ ID NO: 38)-SSSDQS (hereinafter referred to as Example 59);
SDEQRT-(SEQ ID NO: 38)-A (hereinafter referred to as Example 61);
DDEITQ-(SEQ ID NO: 38)-A (hereinafter referred to as Example 64);
RTDETG-(SEQ ID NO: 38)-A (hereinafter referred to as Example 67);
A-(SEQ ID NO: 38)-A (hereinafter referred to as Example 68);
ETNNLE-(SEQ ID NO: 38)-A (hereinafter referred to as Example 71);
Ac-(SEQ ID NO: 38) (hereinafter referred to as Example 79);
DPPKPR-(SEQ ID NO: 38)-A (hereinafter referred to as Example 87);
(SEQ ID NO: 38)-DTSTHS (hereinafter referred to as Example 128);
Ac-(SEQ ID NO: 39) (hereinafter referred to as Example 44);
Ac-(SEQ ID NO: 40) (hereinafter referred to as Example 46);
Ac-(SEQ ID NO: 41) (hereinafter referred to as Example 47);
Ac-(SEQ ID NO: 42) (hereinafter referred to as Example 50);
Ac-(SEQ ID NO: 43) (hereinafter referred to as Example 51);
Ac-(SEQ ID NO: 44) (hereinafter referred to as Example 52);
Ac-(SEQ ID NO: 45) (hereinafter referred to as Example 57);
Ac-(SEQ ID NO: 46) (hereinafter referred to as Example 58);
Ac-(SEQ ID NO: 47) (hereinafter referred to as Example 60);
Ac-(SEQ ID NO: 48) (hereinafter referred to as Example 62);
A-(SEQ ID NO: 49)-ADS (hereinafter referred to as Example 63);
Ac-(SEQ ID NO: 50) (hereinafter referred to as Example 65);
Ac-(SEQ ID NO: 51) (hereinafter referred to as Example 66);
Ac-(SEQ ID NO: 52) (hereinafter referred to as Example 70);
Ac-(SEQ ID NO: 53) (hereinafter referred to as Example 72);
SPP-(SEQ ID NO: 54)-A (hereinafter referred to as Example 73);
Ac-(SEQ ID NO: 55) (hereinafter referred to as Example 74);
A-(SEQ ID NO: 56)-HLE (hereinafter referred to as Example 75);
A-(SEQ ID NO: 57)-A (hereinafter referred to as Example 76);
Ac-(SEQ ID NO: 58) (hereinafter referred to as Example 77);
Ac-(SEQ ID NO: 59) (hereinafter referred to as Example 78);
Ac-(SEQ ID NO: 60) (hereinafter referred to as Example 80);
Ac-(SEQ ID NO: 61) (hereinafter referred to as Example 81);
Ac-(SEQ ID NO: 62) (hereinafter referred to as Example 82);
Ac-(SEQ ID NO: 63) (hereinafter referred to as Example 83);
tertBuCO-(SEQ ID NO: 64) (hereinafter referred to as Example 84);
R1-(SEQ ID NO: 64) (hereinafter referred to as Example 89);
R2-(SEQ ID NO: 64) (hereinafter referred to as Example 95);
Benzyl-(SEQ ID NO: 64) (hereinafter referred to as Example 93);
Ac-(SEQ ID NO: 64)-[N-phenethylamide] (hereinafter referred to as Example 96);
R3-(SEQ ID NO: 64) (hereinafter referred to as Example 99);
R4-(SEQ ID NO: 64) (hereinafter referred to as Example 103);
Ac-(SEQ ID NO: 64)-[N-benzylamide] (hereinafter referred to as Example 109);
A-(SEQ ID NO: 64)-A (hereinafter referred to as Example 115);
Benzoyl-(SEQ ID NO: 64) (hereinafter referred to as Example 116);
Ac-(SEQ ID NO: 64)-R5 (hereinafter referred to as Example 120);
Succinyl-(SEQ ID NO: 64) (hereinafter referred to as Example 121);
Ac-(SEQ ID NO: 64)-[N-octylamide] (hereinafter referred to as Example 122);
Ac-(SEQ ID NO: 64)-[N-pentylamide] (hereinafter referred to as Example 123);
Ac-(SEQ ID NO: 64) (hereinafter referred to as Example 124);
Ac-(SEQ ID NO: 64)-R6 (hereinafter referred to as Example 127);
(SEQ ID NO: 64) (hereinafter referred to as Example 129);
Decanoyl-(SEQ ID NO: 64) (hereinafter referred to as Example 137);
Hexanoyl-(SEQ ID NO: 64) (hereinafter referred to as Example 139);
SPT-(SEQ ID NO: 65)-A (hereinafter referred to as Example 85);
Ac-(SEQ ID NO: 66) (hereinafter referred to as Example 86);
TIK-(SEQ ID NO: 67)-A (hereinafter referred to as Example 88);
Ac-(SEQ ID NO: 68) (hereinafter referred to as Example 90);
Ac-(SEQ ID NO: 69) (hereinafter referred to as Example 91);
Ac-(SEQ ID NO: 70) (hereinafter referred to as Example 92);
Ac-(SEQ ID NO: 71) (hereinafter referred to as Example 94);
DNH-(SEQ ID NO: 72)-A (hereinafter referred to as Example 97);
HPN-(SEQ ID NO: 73)-A (hereinafter referred to as Example 98);
Ac-(SEQ ID NO: 74)-TTS (hereinafter referred to as Example 100);
A-(SEQ ID NO: 75)-A (hereinafter referred to as Example 101);
(SEQ ID NO: 76) (hereinafter referred to as Example 102);
Ac-(SEQ ID NO: 76) (hereinafter referred to as Example 104);
Ac-(SEQ ID NO: 77) (hereinafter referred to as Example 105);
DQD-(SEQ ID NO: 78)-A (hereinafter referred to as Example 106);
Ac-(SEQ ID NO: 79) (hereinafter referred to as Example 107);
Ac-(SEQ ID NO: 80) (hereinafter referred to as Example 108);
Ac-(SEQ ID NO: 81) (hereinafter referred to as Example 110);
Ac-(SEQ ID NO: 82) (hereinafter referred to as Example 111);
Ac-(SEQ ID NO: 83) (hereinafter referred to as Example 112);
Ac-(SEQ ID NO: 84) (hereinafter referred to as Example 113);
Ac-(SEQ ID NO: 85) (hereinafter referred to as Example 114);
REN-(SEQ ID NO: 86)-A (hereinafter referred to as Example 117);
Ac-(SEQ ID NO: 87) (hereinafter referred to as Example 118);
Ac-(SEQ ID NO: 88) (hereinafter referred to as Example 119);
A-(SEQ ID NO: 89)-HEE (hereinafter referred to as Example 125);
Ac-(SEQ ID NO: 90) (hereinafter referred to as Example 126);
Ac-(SEQ ID NO: 91) (hereinafter referred to as Example 130);
Ac-(SEQ ID NO: 92) (hereinafter referred to as Example 131);
Ac-(SEQ ID NO: 93) (hereinafter referred to as Example 132);
Ac-(SEQ ID NO: 94) (hereinafter referred to as Example 133);
Ac-(SEQ ID NO: 95) (hereinafter referred to as Example 134);
Ac-(SEQ ID NO: 96) (hereinafter referred to as Example 135);
A-(SEQ ID NO: 97)-HSE (hereinafter referred to as Example 136);
A-(SEQ ID NO: 98)-ETA (hereinafter referred to as Example 138);
Ac-(SEQ ID NO: 99) (hereinafter referred to as Example 140);
A-(SEQ ID NO: 100)-A (hereinafter referred to as Example 141);
Ac-(SEQ ID NO: 101) (hereinafter referred to as Example 142);
Ac-(SEQ ID NO: 102) (hereinafter referred to as Example 143);
Ac-(SEQ ID NO: 103) (hereinafter referred to as Example 144);
Ac-(SEQ ID NO: 104) (hereinafter referred to as Example 145);
Ac-(SEQ ID NO: 105) (hereinafter referred to as Example 146);
Ac-(SEQ ID NO: 106) (hereinafter referred to as Example 147);
Ac-(SEQ ID NO: 107) (hereinafter referred to as Example 148);
Ac-(SEQ ID NO: 108) (hereinafter referred to as Example 149);
A-(SEQ ID NO: 109)-A (hereinafter referred to as Example 150);
Ac-(SEQ ID NO: 110) (hereinafter referred to as Example 151);
Ac-(SEQ ID NO: 111) (hereinafter referred to as Example 152);
Ac-(SEQ ID NO: 112) (hereinafter referred to as Example 153);
Ac-(SEQ ID NO: 113) (hereinafter referred to as Example 154);
Ac-(SEQ ID NO: 114) (hereinafter referred to as Example 155);
(SEQ ID NO: 114) (hereinafter referred to as Example 156);
Ac-(SEQ ID NO: 115) (hereinafter referred to as Example 157);
Ac-(SEQ ID NO: 116) (hereinafter referred to as Example 158);
Ac-(SEQ ID NO: 117) (hereinafter referred to as Example 159); and
Ac-(SEQ ID NO: 118) (hereinafter referred to as Example 160);, wherein Ac represents acetyl, tertBuCO represents, , R1 represents:, , R2 represents:, , R3 represents:, , R4 represents:, , R5 represents:, , and, R6 represents:, , or a pharmaceutically acceptable salt thereof.